Patents by Inventor Craig Flanagan

Craig Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786687
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 17, 2023
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 11759620
    Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: September 19, 2023
    Assignee: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
    Inventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
  • Patent number: 11324912
    Abstract: The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO2, and providing an indication of the remaining useful life and/or break-through.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 10, 2022
    Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
    Inventors: Jaron Acker, Muhammad Asif, Craig Flanagan, Douglas Alan Greene, Sarah Jayne Ridley, Frank Kenneth Schweighardt, Lien-Lung Sheu
  • Patent number: 11202899
    Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: December 21, 2021
    Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
    Inventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
  • Publication number: 20210330957
    Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
    Type: Application
    Filed: June 25, 2021
    Publication date: October 28, 2021
    Inventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
  • Publication number: 20210260327
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 26, 2021
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 11065415
    Abstract: The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 20, 2021
    Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
    Inventors: Craig Flanagan, David Newman, Jaron M. Acker, Craig R. Tolmie, Jim Potenziano
  • Patent number: 10918819
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: February 16, 2021
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20200171259
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Application
    Filed: February 10, 2020
    Publication date: June 4, 2020
    Applicant: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20200094010
    Abstract: The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO2, and providing an indication of the remaining useful life and/or break-through.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Inventors: Jaron Acker, Muhammad Asif, Craig Flanagan, Douglas Alan Greene, Sarah Jayne Ridley, Frank Kenneth Schweighardt, Lien-Lung Sheu
  • Patent number: 10556082
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 11, 2020
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 10525226
    Abstract: The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO2, and providing an indication of the remaining useful life and/or break-through.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: January 7, 2020
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Jaron Acker, Muhammad Asif, Craig Flanagan, Douglas Alan Greene, Sarah Jayne Ridley, Frank Kenneth Schweighardt, Lien-Lung Sheu
  • Publication number: 20190328574
    Abstract: An automated mandibular advancement device (MAD) is described for the treatment of sleep disorders involving the occlusion of upper airway gas flow during sleep; one example being obstructive sleep apnea. In embodiments, a MAD projects the lower jaw forward only after the patient has fallen asleep. Embodiments of the may track patient sleep parameters for later review by the patient and/or the treating physician to assess the quality of sleep and efficacy of the treatment regime. An actuator placed laterally within a band allows the integral microprocessor to actuate the lower jaw tray forward upon sensing of snoring activity (or upon exceeding a pre-set timer threshold).
    Type: Application
    Filed: May 11, 2019
    Publication date: October 31, 2019
    Inventor: Craig Flanagan
  • Patent number: 10398820
    Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: September 3, 2019
    Assignee: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
    Inventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
  • Patent number: 10376410
    Abstract: An automated mandibular advancement device (MAD) is described for the treatment of sleep disorders involving the occlusion of upper airway gas flow during sleep; one example being obstructive sleep apnea. In embodiments, a MAD projects the lower jaw forward only after the patient has fallen asleep. Embodiments of the may track patient sleep parameters for later review by the patient and/or the treating physician to assess the quality of sleep and efficacy of the treatment regime. An actuator placed laterally within a band allows the integral microprocessor to actuate the lower jaw tray forward upon sensing of snoring activity (or upon exceeding a pre-set timer threshold).
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: August 13, 2019
    Inventor: Craig Flanagan
  • Publication number: 20190216377
    Abstract: The present invention provides devices and methods for calculating and monitoring oxygenation parameters during treatment with delivery of nitric oxide. The devices and methods of the present invention can calculate the oxygenation index based on measurements of mean airway pressure, saturation of oxygen and fraction of inspired oxygen derived from components of the present invention. Also described is a nitric oxide delivery device that incorporates a proximal pressure transducer.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 18, 2019
    Inventors: Craig Flanagan, David Newman, Jaron Acker, Craig R. Tolmie
  • Publication number: 20190111230
    Abstract: The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventors: Craig Flanagan, David Newman, Jaron M. Acker, Craig R. Tolmie, Jim Potenziano
  • Publication number: 20190046705
    Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
    Type: Application
    Filed: January 30, 2017
    Publication date: February 14, 2019
    Inventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
  • Patent number: 10188822
    Abstract: The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: January 29, 2019
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, David Newman, Jaron M. Acker, Craig R. Tolmie, Jim Potenziano
  • Patent number: 10130783
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: November 20, 2018
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah